HeartFlow’s $364m initial public offering (IPO) signals market validation for the use of artificial intelligence (AI) in a medtech company’s product portfolio, an expert says. Roundly exceeding its $300m expectations for the IPO, the Bain Capital-backed AI-based coronary artery disease (CAD) platform developer debuted with a a $2.2bn valuation on the Nasdaq on 8 August. Medtech industry veteran, Brent Ness, CEO of Aclarion, who served as HeartFlow’s chief commercial officer from 2014 to 2015, told Medical Device Network that HeartFlow’s work on the underlying economic factors around its product, including working on contractual relationships with imaging centres to get them on board with the product, pre-reimbursement, have proven a key part of its success.
Read the full article: Heartflow IPO Success Reflects Market Embrace of AI in Medtech Industry //
Source: https://www.medicaldevice-network.com/news/heartflow-ipo-success-reflects-market-embrace-of-ai-in-medtech-industry/